Sugi Predict

Sugi Predict / Compounds / SCHEMBL62966

SCHEMBL62966

SCHEMBL62966

N#CC1(O)CCN(Cc2ccccc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.65
▸ OPRL1 P41146 4/20 0.61
▸ POLB P06746 1/20 0.59
▸ CYP3A4 P08684 3/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ CCR3 P51677 1/20 0.55
▸ SIGMAR1 Q99720 6/20 0.55
▸ TSHR P16473 3/20 0.51
▸ CYP2C19 P33261 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ CYP2C9 P11712 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ CYP2D6 P10635 3/20 0.51
▸ TP53 P04637 2/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ DRD2 P14416 1/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ HTR2A P28223 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1147552 0.98 OPRM1 (0.63) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL17714554 0.94 OPRM1 (0.58) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL15325219 0.90 OPRM1 (0.57) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL5741800 0.84 OPRM1 (0.49) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL2796888 0.84 OPRL1 (0.49) OPRM1OPRL1SIGMAR1ALDH1A1MEN1
SCHEMBL27685545 0.84 SMN1; SMN2 (0.62) OPRM1SIGMAR1DRD2HTR2AHTR2C
SCHEMBL4462838 0.83 OPRL1 (0.61) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL12022949 0.83 OPRM1 (0.69) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL3495380 0.81 CYP2D6 (0.52) OPRM1OPRL1POLBCYP3A4HSD17B10
SCHEMBL9231786 0.81 OPRM1 (0.61) OPRM1OPRL1POLBCYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646263-A1 SPRK1 INHIBITORS AND METHODS OF USE Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2025-11-12 — — EP disclosed
US-20250034193-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2025-01-30 — — US disclosed
US-12145963-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2024-11-19 — — US disclosed
WO-2024155864-A1 SPRK1 INHIBITORS AND METHODS OF USE ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2024-07-25 — — WO disclosed
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 — — EP disclosed
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2024-04-18 — — US disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 — — US disclosed
EP-4263520-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2023-10-25 — — EP disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 — — US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 — — US disclosed
EP-1399160-A2 NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES Merck & Co., Inc. (US) 2004-03-24 — — EP disclosed
EP-1379520-A1 N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2004-01-14 — — EP disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 — — WO disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 — — WO disclosed
WO-2003010138-A2 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2003-02-06 — — WO disclosed
WO-2002100352-A2 NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES MERCK & CO., INC. (US) 2002-12-19 — — WO disclosed
US-20020165241-A1 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK SHARP & DOHME LLC 2002-11-07 — — US disclosed
WO-2002068409-A1 N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2002-09-06 — — WO disclosed
US-5739336-A SELECTIVE 5-HYDROXYTRYPTAMINE-2C RECEPTOR ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1998-04-14 — — US disclosed
WO-1997000872-A1 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO(4,5)DECANE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 1997-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG OPRM1 984/4885OPRL1 957/4885POLB 2788/4885
US-20240124428-A1 HETEROCYCLIC INHIBITORS OF PCSK9 PCSK9, PCSK7, PCSK6 OPRM1 4192/4885OPRL1 1730/4885POLB 2895/4885
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 OPRM1 3230/4885OPRL1 2444/4885POLB 306/4885
US-12145963-B2 Phenothiazine derivatives and uses thereof RPLP2, RPS2, RPLP1 OPRM1 3230/4885OPRL1 2444/4885POLB 306/4885
US-20250034193-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 OPRM1 3230/4885OPRL1 2444/4885POLB 306/4885
US-20020165241-A1 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists GRIN1, GRIN2B, GRIN2A OPRM1 39/4885OPRL1 10/4885POLB 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.